Delivery Order SPE2DB22D1202-SPE2DB24FVKK5

Award Date 8/9/24
Potential Completion Date 8/12/24
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The award has a ceiling value of $1,121.36 and is for the delivery of clindamycin phosphate 1% lotion, a topical antibiotic medication. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Clindamycin Phosphate 1% Lotion, a prescription topical medication. The contract has a ceiling value of $1,580.77 and a period of performance through December 5, 2024. The contract is classified as Firm Fixed Price and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $1,348.34 to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of 4,564,327,564 units of Clindamycin Phosphate 1% Lotion in 60 mL containers. This order is under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,064 firm-fixed-price delivery order is for the supply of Clindamycin Phosphate 1% Lotion, a topical antimicrobial medication. The contract has an ultimate completion date of September 19, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This contract award, valued at $4,033.29, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4565046317 - Clindamycin Phosphate 1% Lotion 60ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a performance period through July 2, 2024. This contract award is not associated with a set-aside program. AmerisourceBergen Drug Corp...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Clindamycin Phosphate 1% Lotion 60ML. The firm-fixed-price contract has a ceiling value of $1,591.79 and runs through January 31, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award is for the delivery of Clindamycin Phosphate 1% Lotion, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order with a Firm Fixed Price type, valued at $3,316.56, and has an Ultimate Completion Date of March 13, 2024. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award, valued at $1,828.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution company. The contract is for the delivery of Clindamycin Phosphate 1% Lotion, a topical antimicrobial medication, to support military healthcare programs. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up...
This federal contract award, valued at $2,603.84, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Clindamycin Phosphate 1% Lotion, a pharmaceutical product. The award represents a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as...
This contract award, valued at $2,709.94, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB24FVKK5
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Clindamycin Phosphate 1% Lotion, a prescription medication. The $1,752.05 firm-fixed-price delivery order has an ultimate completion date of August 12, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation.

Generated 11/8/24, 9:23 AM